ID   THP-1/E
AC   CVCL_A1RT
DR   cancercelllines; CVCL_A1RT
DR   Wikidata; Q105511202
RX   PubMed=2633408;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16).
CC   Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9163; Childhood acute monocytic leukemia
DI   ORDO; Orphanet_514; Acute monoblastic/monocytic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0006 ! THP-1
SX   Male
AG   1Y
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 05-10-23; Version: 5
//
RX   PubMed=2633408; DOI=10.1620/tjem.159.299;
RA   Saijo Y., Kumano N., Tokue Y., Satoh K., Oizumi K., Motomiya M.;
RT   "Characterization of resistance to VP-16 in human leukemic cell
RT   line.";
RL   Tohoku J. Exp. Med. 159:299-306(1989).
//